Does Blue Cross Blue Shield of Michigan Cover Jardiance?

BCBSM Formulary Placement for Jardiance

Blue Cross Blue Shield of Michigan places Jardiance (empagliflozin) on its preferred brand formulary tier for the majority of commercial group and individual plans. This means members can access the medication with a brand-tier copay rather than paying the full retail price, which averages around $570 for a 30-day supply without insurance according to FDA-approved labeling and pricing data.

Formulary placement can shift between Tier 2 and Tier 3 depending on the specific plan purchased. Employer-sponsored groups sometimes negotiate custom formularies that move Jardiance to a higher or lower cost-sharing tier. The American Diabetes Association's Standards of Care recommend SGLT2 inhibitors as a preferred second-line agent after metformin for patients with established cardiovascular disease or chronic kidney disease, which supports insurer coverage of this drug class. Blue Care Network (BCN), the HMO arm of BCBSM, carries Jardiance on a comparable tier with similar cost-sharing, though BCN plans may enforce tighter network pharmacy requirements.

Members should verify their specific formulary through the BCBSM member portal or by calling the number on the back of their insurance card. Formularies update annually, typically in January, and mid-year changes are rare but possible for commercial plans.

Prior Authorization and Step Therapy Requirements

BCBSM requires prior authorization for Jardiance on select plans, particularly Medicare Advantage and some individual marketplace products. The prior authorization process verifies that the prescribing physician has documented a qualifying diagnosis and, in many cases, that the patient has tried and failed first-line therapy.

Step therapy is common. BCBSM frequently mandates a trial of metformin, the first-line agent recommended by the ADA, before approving an SGLT2 inhibitor. A typical step therapy protocol requires 60 to 90 days of metformin use (or documented intolerance) before Jardiance is authorized. Patients with established atherosclerotic cardiovascular disease (ASCVD) may qualify for a step therapy override, because guidelines from the American Association of Clinical Endocrinology support using SGLT2 inhibitors as initial combination therapy with metformin in this population.

The prior authorization form requires the prescriber to supply: the patient's current A1C level, a list of previously tried diabetes medications, relevant comorbidities (heart failure, CKD, ASCVD), and the rationale for choosing empagliflozin over alternatives. Approval decisions typically take 24 to 72 hours. If denied, patients have the right to appeal through BCBSM's standard appeals process.

What You Can Expect to Pay

Out-of-pocket costs for Jardiance under BCBSM plans vary widely based on plan design, deductible status, and pharmacy network. Here is a general breakdown.

On commercial PPO plans with a standard three-tier formulary, Jardiance copays typically fall between $35 and $75 per month once the deductible is met. High-deductible health plans (HDHPs) paired with a health savings account require patients to pay the full negotiated rate until meeting their annual deductible, which can mean $400 or more per fill early in the plan year. The FDA's Orange Book listing for empagliflozin confirms no generic equivalent is currently available, keeping costs higher than genericized diabetes drugs.

Medicare Advantage members enrolled in BCBSM plans face cost-sharing that follows the Medicare Part D benefit structure. During the initial coverage phase, copays or coinsurance range from $42 to $100 per month. After reaching the catastrophic coverage threshold ($8 to 000 in true out-of-pocket spending for 2025) as defined by CMS, costs drop to 5% coinsurance or a small copay.

Boehringer Ingelheim offers a manufacturer savings card that can reduce copays to as little as $10 per month for commercially insured patients. This card is not valid for Medicare, Medicaid, or other federal healthcare program beneficiaries. Eligible patients can save up to $175 per 30-day prescription.

Why Insurers Cover Jardiance: The Clinical Evidence

BCBSM's decision to cover Jardiance reflects the medication's strong evidence base across three major indications. That evidence drives formulary committees to classify it as medically necessary rather than optional.

The EMPA-REG OUTCOME trial (N=7,020) was the landmark study. Published in the New England Journal of Medicine in 2015, it showed empagliflozin reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49 to 0.77, P<0.001) compared with placebo in patients with type 2 diabetes and established cardiovascular disease. All-cause mortality decreased by 32%. These results shifted treatment guidelines worldwide.

For heart failure, the EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the combined risk of cardiovascular death or heart failure hospitalization by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure with reduced ejection fraction, regardless of diabetes status. The EMPEROR-Preserved trial (N=5,988) extended these findings to heart failure with preserved ejection fraction, making empagliflozin the first drug to show benefit across the full spectrum of heart failure.

In chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001). The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines now recommend SGLT2 inhibitors for patients with CKD and an eGFR of 20 mL/min or above, a recommendation that directly influences insurer coverage determinations.

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine and a principal investigator in the EMPA-REG OUTCOME trial, has stated: "The cardiovascular mortality benefit observed with empagliflozin was unprecedented for a glucose-lowering drug. These data changed how we think about diabetes treatment."

How Jardiance Compares to Other Covered SGLT2 Inhibitors

BCBSM formularies typically cover multiple SGLT2 inhibitors, and understanding the tier placement of each can affect your out-of-pocket costs. The three most commonly covered options are empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).

Dapagliflozin often holds a comparable formulary position to empagliflozin on BCBSM plans. The DAPA-HF trial (N=4,744) and the DAPA-CKD trial (N=4,304) demonstrated similar cardiovascular and kidney benefits for dapagliflozin. In some plan years, BCBSM may prefer one over the other based on rebate negotiations with manufacturers.

Canagliflozin is sometimes placed on a less favorable tier. While the CANVAS Program (N=10,142) showed cardiovascular benefit, an early signal for increased amputation risk (6.3 vs. 3.4 per 1,000 patient-years) led some formulary committees to position it behind empagliflozin and dapagliflozin. Subsequent real-world data have been more reassuring, but the initial signal still affects tier placement at some insurers.

If your BCBSM plan prefers Farxiga over Jardiance (or vice versa), your physician can submit a formulary exception request. Approval requires documentation that the preferred alternative was tried without adequate response, caused intolerable side effects, or is contraindicated. The ADA's consensus report on SGLT2 inhibitor selection notes that individual patient factors, including kidney function, cardiovascular risk profile, and concomitant medications, should guide drug selection within the class.

Michigan-Specific Coverage Considerations

Michigan's insurance regulatory environment shapes how BCBSM administers Jardiance coverage in ways that differ from Blue Cross plans in other states. BCBSM operates as a nonprofit mutual insurer, which means its formulary decisions are made independently from the for-profit Anthem/Elevance Blue Cross affiliates in other regions.

The Michigan Department of Insurance and Financial Services (DIFS) requires all state-regulated health plans to cover prescription drugs classified as "essential health benefits" under the Affordable Care Act's benchmark plan requirements. Diabetes medications fall within this mandate. BCBSM must cover at least one drug in each pharmacological class, and in practice, the plan covers multiple SGLT2 inhibitors.

Michigan has no state-level mandate requiring coverage of specific brand-name diabetes medications. This means BCBSM has discretion to impose step therapy, prior authorization, and quantity limits on Jardiance. Some employer groups in Michigan's automotive and manufacturing sectors negotiate richer pharmacy benefits that waive prior authorization requirements or place Jardiance on a lower copay tier.

For Medicaid managed care, Michigan's Healthy Michigan Plan covers SGLT2 inhibitors under the state's preferred drug list, administered separately from BCBSM commercial plans. Dual-eligible patients (those with both Medicare and Medicaid) follow Medicare Part D formulary rules for outpatient prescription drugs.

How to Get Jardiance Approved Through BCBSM

Getting Jardiance covered requires coordination between you and your prescriber. The process is straightforward.

First, confirm your formulary. Log into the BCBSM member portal or call member services to check whether Jardiance is on your plan's drug list and which tier it occupies. Request a copy of your Summary of Benefits and Coverage (SBC), which lists copay amounts by tier.

Second, ask your doctor to complete any required prior authorization. The prescriber's office submits clinical documentation through BCBSM's electronic prior authorization system. Key elements include your A1C level (typically must be 7.0% or above, consistent with the ADA's glycemic target recommendations), documentation of metformin trial or contraindication, and listing of relevant comorbidities.

Third, use a network pharmacy. BCBSM offers lower cost-sharing at in-network retail pharmacies and mail-order pharmacy services. A 90-day mail-order supply typically saves 15% to 25% compared with three separate 30-day retail fills.

Fourth, apply manufacturer and third-party assistance. The Boehringer Ingelheim savings card works at the point of sale for commercially insured patients. Patients facing financial hardship can also explore the Boehringer Ingelheim Cares Foundation patient assistance program, which provides Jardiance at no cost to qualifying uninsured or underinsured individuals.

The Endocrine Society's clinical practice guidelines support empagliflozin as a first-line add-on agent to metformin in patients with type 2 diabetes and high cardiovascular risk. Citing this guideline in a prior authorization appeal strengthens the case for approval.

Safety Profile and Monitoring Under Coverage

BCBSM coverage of Jardiance includes access to necessary monitoring labs. Understanding the safety profile helps you know what to expect.

Common side effects include genital mycotic infections (occurring in approximately 6% to 8% of women and 3% to 4% of men in clinical trials), urinary tract infections, and increased urination. The FDA prescribing information for Jardiance includes warnings about diabetic ketoacidosis (DKA), which can occur rarely even at normal blood glucose levels (euglycemic DKA), and Fournier's gangrene, an extremely rare but serious necrotizing fasciitis of the perineum.

Kidney function monitoring is standard. Prescribers typically check serum creatinine and eGFR before starting Jardiance and periodically thereafter. The KDIGO guidelines note that an initial eGFR dip of 10% to 30% is expected and hemodynamically mediated, not a reason to discontinue the drug. BCBSM covers these monitoring labs as part of standard preventive and chronic disease management benefits.

Dr. David Cherney, clinician-scientist at the University of Toronto and a leading SGLT2 inhibitor researcher, has observed: "The initial eGFR decline with SGLT2 inhibitors reflects reduced glomerular hyperfiltration. It is a sign the drug is working, not a signal to stop it."

Blood pressure typically drops 3 to 5 mmHg systolic on empagliflozin, per data from the EMPA-REG BP substudy. Patients on antihypertensives may need dose adjustments. Body weight decreases an average of 2 to 3 kg over 6 to 12 months, driven by caloric loss through glycosuria (approximately 70 g of glucose excreted daily at an A1C of 8%).

Patients should be counseled to maintain adequate hydration, recognize symptoms of ketoacidosis (nausea, vomiting, abdominal pain, fatigue, difficulty breathing), and report any genital or perineal symptoms promptly. Jardiance should be held 3 to 4 days before scheduled surgery to minimize perioperative DKA risk.